Filters

Search for: [Abstract = "Depression is the leading cause of disability and the 4th highest contributor to the global disease burden in the twenty\-first century. Despite the existence of several preclinical and clinical studies, the pathophysiology of this brain disorder remains still unclear. On the one hand, currently prescribed antidepressants do not meet requirements of patients and clinicians, on the another hand – despite the well\-documented the role of stress, infectious agents, and genetic influence in depression \- the cause\(s\) of the disorder have not yet been completely elucidated. Several antidepressants with different mechanisms of action are commonly used in the clinic, which suggests that not the particular drug\-target interaction is responsible for the drug therapeutic efficacy\; instead, there is likely that a secondary effect of such interaction is important. The endocannabinoid system is involved in modulating emotional responses, memory and learning, and several previous studies have implicated this system in the pathogenesis of depression. Furthermore, it is believed that mechanisms by which the endocannabinoid system may interfere with emotional states associated with depression of action include neuroanatomical localization of CB1 receptors linked to depression, with modulation of monoaminergic transmission, inhibition of the stress axis and\/or promotion of neuroplasticity in the brain"]

Number of results: 1

items per page

This page uses 'cookies'. More information